Back to results
US 6,887,660 B2Granted
Compounds for immunodiagnosis of prostate cancer and methods for their use
AssigneeCorixa Corporation
InventorsJiangchun Xu, Davin C. Dillon
Life of this patent
Estimating the term…
Abstract
Compounds and methods for diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. The inventive polypeptides may be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.
Claims2
A method for detecting prostate cancer in a patient comprising:
- (a) obtaining a biological sample from the patient;
- (b) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein said oligonucleotide primers are specific for nucleotide residues 1341-2694 of SEQ ID NO:110 an full length complements of nucleotide residues 1341-2694 of SEQ ID NO:110;
- and
- (c) detecting in the sample an expressed polynucleotide sequence that amplifies in the presence of the oligonucleotide primers thereby detecting prostate cancer, wherein the biological sample is selected from the group consisting of blood and semen;
- wherein the oligonucleotide primers consist of fragments of nucleotide residues 1341-2694 of SEQ ID NO:110;
- and wherein the fragments consist of at least about 10 contiguous nucleotides of nucleotide residues 1341-2694 of SEQ ID NO:110, or full length complements of nucleotide residues 1341-2694 of SEQ ID NQ:110.
3 more elements
A method for detecting the presence of an expressed polynucleotide sequence of SEQ ID NO:
- 110 in a biological sample, the method comprising:
- (a) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein the oligonucleotide primers are specific for nucleotide residues 1341-2694 of SEQ ID NO:110 and full length complements of nucleotide residues 1341-2694 of SEQ ID NO:110;
- and
- (c) detecting in the sample an expressed polynucleotide sequence that amplifies in the presence of the oligonucleotide primers thereby detecting prostate cancer, wherein the biological sample is selected from the group consisting of blood and semen;
- wherein the oligonucleotide primers consist of fragments of nucleotide residues 1341-2694 of SEQ ID NO:110;
- and wherein the fragments consist of at least about 10 contiguous nucleotides of nucleotide residues 1341-2694 of SEQ ID NO:110, or full length complements of nucleotide residues 1341-2694 of SEQ ID NO:110.
3 more elements
Dependencies are inferred from the claim text.